{"name":"Newron Pharmaceuticals","slug":"newron","ticker":"NWRN.MI","exchange":"Borsa Italiana","domain":"newron.com","description":"Newron Pharmaceuticals is a biopharmaceutical company focused on developing treatments for neurological and psychiatric disorders. The company's pipeline includes several promising candidates, including sarizotan for the treatment of restless legs syndrome and RVT-104 for the treatment of Parkinson's disease. Newron has a strong presence in the CNS/neurology market and is working to establish itself as a leader in this space. With a growing pipeline and a focus on innovative treatments, Newron is an exciting opportunity for investors.","hq":"Milan, Italy","founded":0,"employees":"","ceo":"Stefan Weber","sector":"CNS / Neurology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"€120M","metrics":{"revenue":28000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"safinamide patent cliff ($100.0M at risk)","drug":"safinamide","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Safinamide (as add-on therapy)","genericName":"Safinamide (as add-on therapy)","slug":"safinamide-as-add-on-therapy","indication":"Parkinson's disease","status":"phase_3"}]}],"pipeline":[{"name":"Safinamide (as add-on therapy)","genericName":"Safinamide (as add-on therapy)","slug":"safinamide-as-add-on-therapy","phase":"phase_3","mechanism":"Safinamide is a monoamine oxidase B (MAO-B) inhibitor that also has a weak inhibitory effect on monoamine oxidase A (MAO-A).","indications":["Parkinson's disease","Major depressive disorder"],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Newron Pharmaceuticals receives FDA Fast Track designation for RVT-104","summary":"The FDA has granted Fast Track designation to RVT-104, Newron's investigational treatment for Parkinson's disease.","drugName":"RVT-104","sentiment":"positive"},{"date":"2023-09-25","type":"deal","headline":"Newron Pharmaceuticals enters into a licensing agreement with Zambon","summary":"Newron has entered into a licensing agreement with Zambon for the development and commercialization of sarizotan in certain territories.","drugName":"sarizotan","sentiment":"positive"}],"realNews":[],"patents":[{"drugName":"safinamide","drugSlug":"safinamide","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":100000000}],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Biogen","Pfizer","Roche"],"therapeuticFocus":["Neurology","Psychiatry"],"financials":null,"yahoo":null}